JP2024530021A5 - - Google Patents

Info

Publication number
JP2024530021A5
JP2024530021A5 JP2024506860A JP2024506860A JP2024530021A5 JP 2024530021 A5 JP2024530021 A5 JP 2024530021A5 JP 2024506860 A JP2024506860 A JP 2024506860A JP 2024506860 A JP2024506860 A JP 2024506860A JP 2024530021 A5 JP2024530021 A5 JP 2024530021A5
Authority
JP
Japan
Application number
JP2024506860A
Other languages
Japanese (ja)
Other versions
JPWO2023016826A5 (https=
JP2024530021A (ja
Filing date
Publication date
Priority claimed from PCT/EP2022/052148 external-priority patent/WO2022162203A1/en
Application filed filed Critical
Priority claimed from PCT/EP2022/071294 external-priority patent/WO2023016826A2/en
Publication of JP2024530021A publication Critical patent/JP2024530021A/ja
Publication of JPWO2023016826A5 publication Critical patent/JPWO2023016826A5/ja
Publication of JP2024530021A5 publication Critical patent/JP2024530021A5/ja
Pending legal-status Critical Current

Links

JP2024506860A 2021-08-05 2022-07-28 治療用抗体の増強のための方法及び手段 Pending JP2024530021A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21189996.8 2021-08-05
EP21189996 2021-08-05
PCT/EP2022/052148 WO2022162203A1 (en) 2021-01-28 2022-01-28 Method and means for modulating b-cell mediated immune responses
EPPCT/EP2022/052148 2022-01-28
PCT/EP2022/071294 WO2023016826A2 (en) 2021-08-05 2022-07-28 Method and means for enhancing therapeutic antibodies

Publications (3)

Publication Number Publication Date
JP2024530021A JP2024530021A (ja) 2024-08-14
JPWO2023016826A5 JPWO2023016826A5 (https=) 2025-08-04
JP2024530021A5 true JP2024530021A5 (https=) 2025-08-04

Family

ID=84331532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506860A Pending JP2024530021A (ja) 2021-08-05 2022-07-28 治療用抗体の増強のための方法及び手段

Country Status (8)

Country Link
US (1) US20250326863A1 (https=)
EP (1) EP4380616A2 (https=)
JP (1) JP2024530021A (https=)
KR (1) KR20240042011A (https=)
CN (1) CN117120084A (https=)
AU (1) AU2022325425A1 (https=)
CA (1) CA3225923A1 (https=)
WO (1) WO2023016826A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023346A1 (en) * 2022-07-28 2024-02-01 Vaccinvent Gmbh Igm antibodies degrading igg

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 FcγRIIIa多型患者に適応する抗体組成物含有医薬
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
FR2871633A1 (fr) 2004-06-10 2005-12-16 France Telecom Procede de reduction du bruit de phase lors de la reception d'un signal ofdm, recepteur, programme et support
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2017024404A1 (en) * 2015-08-10 2017-02-16 Network Immunology Inc. Modification of the immune system by antigen-specific plus antiidiotypic antibodies
US20220356232A1 (en) * 2019-06-28 2022-11-10 Network Immunology Inc. A combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of autoimmune diseases

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
JP2024530021A5 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BY23965C1 (https=)
BY13156U (https=)
CN307047952S (https=)
CN307046885S (https=)
CN307048444S (https=)
CN307046274S (https=)
CN307046042S (https=)
CN307045812S (https=)
CN307045758S (https=)
CN307045546S (https=)
CN307045350S (https=)
CN307044998S (https=)
CN307048615S (https=)
CN307044755S (https=)
CN307044247S (https=)
BY24009C1 (https=)
BY13157U (https=)